The AACR-Pezcoller Foundation Scholar-in-Training Awards continue the AACR’s long-standing support of the next generation of cancer researchers, aimed:
- to enhance participation in the programs and activities of the AACR by early-career investigators residing in Europe
- to provide these outstanding Scholar-in-Training Awardees with an opportunity to share their research findings with the international cancer research community at the AACR Annual Meeting.
Scholar-in-Training Awards are highly competitive and recognize outstanding young investigators presenting meritorious proofreader papers at the AACR Annual Meeting.
Eligibility
- Applicants must be the first author and presenter of an abstract submitted for presentation at the Annual Meeting.
- Applicants must be an Associate Member of the AACR in good standing
- Nonmember graduate students, medical students and residents, clinical fellows or equivalent, and postdoctoral fellows who wish to apply for a
Scholar-in-Training Award should first submit a Membership Application
The 2023 winners of the Pezcoller-AACR Scholar-in-Training Fellowships
- Roberto Ferrara, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan. Project: Circulating immature neutrophils early detect hyperprogressive disease upon first-line PD-1/PD-L1 inhibitors in non-small cell lung cancer patients selecting best candidates for platinum-based chemotherapy and PD-1/PD-L1 inhibitors combinations.
- Giulia Francescato, University of Torino. Project: Fecal miRNA profiles and gut metagenome composition in Lynch syndrome: results from a mouse model study and human subjects
- Sia Lindskrog, Aarhus University Hospital, Denmark. Project: Utility of circulating tumor DNA and transcriptomic profiling in predicting outcome in muscle invasive bladder cancer patients
- Alessia Potenza, University Vita-Salute San Raffaele, Milan. Project: Harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells
- Simone Weiss, Aarhus University Hospital, Denmark. Project: Genome-Scale CRISPRa and CRISPRi screening for lncRNA drivers of prostate cancer progression
- Daniel Zingg, Netherlands Cancer Institute, Amsterdam. Project: Truncated FGFR2 - a clinically actionable oncogene in multiple cancers
